Eli Lilly: Acquired Verve Therapeutics for up to $1.3 billion to advance LNP-based gene editing therapies for cardiovascular disease. Genprex: Presented research on non-viral diabetes gene therapy using lipid nanoparticle delivery system at the American Diabetes Association conference. SNS Insider: Published market report projecting lipid nanoparticles market to reach $2.89 billion by 2032, driven by mRNA technology advances. Nature Nanotechnology: Published study on tailo